Scholarlink

<p>Domperidone (DOM) is a BCS class II drug which widely used as an oral medication for the control of nausea and vomiting. It showed a very low and variable bioavailability related to its very poor solubility and pre-systemic metabolism. Polymeric nanofibers (PNFs) exhibit unique properties that make them a favorable choice for drug delivery applications. The study aimed to develop an optimum fast-dissolving oral polymeric electrospun nanofiber of DOM using Eudragit L100/Polyvinyl alcohol (EL-100/PVA) polymer blend. The fabrication process was optimized through a set of formulation parameters (composition of the polymer blend, polymer blend concentration, and electrospinning voltage). The DOM-loaded EL-100/PVA NFs were characterized for surface shape, nanosize, % drug loading, DOM in vitro release, drug/polymer interaction, and in vivo prokinetic study. The optimization process showed defect-free DOM-loaded NFs with very low nano diameter, high DOM loading, and superior in vitro dissolution of DOM at intestinal pH (about 90% of the drug released within 5&#xa0;min). The drug/polymer interaction study demonstrated the conversion of DOM into an amorphous form, which facilitated its dissolution. No physicochemical interaction between DOM and the polymer blend was observed. I<i>n vivo</i> prokinetic study signified the orally enhanced prokinetic activity of DOM-loaded NF relative to pure DOM and commercial DOM product. The DOM-loaded EL-100/PVA NFs exhibited a better effect on the gastrointestinal reactivity relative to free DOM and commercial DOM product. The superior in vitro dissolution and in vivo prokinetic activity proved the promising potential of polymeric NFs to improve the oral delivery of DOM. The optimized DOM-loaded EL-100/PVA NFs may allow for dose reduction and low cardiovascular risk compared to conventional DOM tablets.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design and preparation of novel domperidone loaded polymeric blend electrospun nanofibers for improved oral pharmacodynamic activity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Kamal Shatla,
  • Eman Sweed,
  • Suleiman Eltokhy,
  • Adel Abdel-Rahman,
  • Abdel Hamid Ismail,
  • Nour Abd El-Sattar,
  • El-Refaie Kenawy,
  • Yusuf Haggag

摘要

Domperidone (DOM) is a BCS class II drug which widely used as an oral medication for the control of nausea and vomiting. It showed a very low and variable bioavailability related to its very poor solubility and pre-systemic metabolism. Polymeric nanofibers (PNFs) exhibit unique properties that make them a favorable choice for drug delivery applications. The study aimed to develop an optimum fast-dissolving oral polymeric electrospun nanofiber of DOM using Eudragit L100/Polyvinyl alcohol (EL-100/PVA) polymer blend. The fabrication process was optimized through a set of formulation parameters (composition of the polymer blend, polymer blend concentration, and electrospinning voltage). The DOM-loaded EL-100/PVA NFs were characterized for surface shape, nanosize, % drug loading, DOM in vitro release, drug/polymer interaction, and in vivo prokinetic study. The optimization process showed defect-free DOM-loaded NFs with very low nano diameter, high DOM loading, and superior in vitro dissolution of DOM at intestinal pH (about 90% of the drug released within 5 min). The drug/polymer interaction study demonstrated the conversion of DOM into an amorphous form, which facilitated its dissolution. No physicochemical interaction between DOM and the polymer blend was observed. In vivo prokinetic study signified the orally enhanced prokinetic activity of DOM-loaded NF relative to pure DOM and commercial DOM product. The DOM-loaded EL-100/PVA NFs exhibited a better effect on the gastrointestinal reactivity relative to free DOM and commercial DOM product. The superior in vitro dissolution and in vivo prokinetic activity proved the promising potential of polymeric NFs to improve the oral delivery of DOM. The optimized DOM-loaded EL-100/PVA NFs may allow for dose reduction and low cardiovascular risk compared to conventional DOM tablets.

Graphical abstract